Mirabegron (Myrbetriq) Manufacturing Plant Project Report 2024: Processes, Costs, and Considerations

Introduction

A Mirabegron (Myrbetriq) Manufacturing Plant Project Report provides a detailed roadmap for establishing a facility that manufactures Mirabegron, the active pharmaceutical ingredient (API) in the brand-name drug Myrbetriq. Myrbetriq is commonly prescribed for the treatment of overactive bladder (OAB) and associated symptoms such as frequent urination, urgency, and incontinence. It works as a selective beta-3 adrenergic receptor agonist, promoting relaxation of the bladder muscles and enhancing the storage capacity of the bladder.

With the increasing demand for medications treating OAB and the growing global awareness of urinary disorders, the market for Mirabegron has seen significant expansion. This project report will provide insights into the necessary steps to set up a Mirabegron manufacturing plant, covering raw material procurement, production processes, regulatory compliance, plant design, and market analysis.

What Is Mirabegron (Myrbetriq)?

Mirabegron, marketed under the brand name Myrbetriq, is a prescription medication used to treat overactive bladder (OAB). OAB is a condition characterized by an urgent need to urinate frequently, often leading to incontinence. Mirabegron works by stimulating the beta-3 adrenergic receptors in the bladder, leading to relaxation of the detrusor muscle (the muscle responsible for bladder contractions), thereby increasing bladder capacity and reducing symptoms of OAB.

Unlike other treatments for OAB, which primarily involve muscarinic receptor antagonists (which can have significant side effects), Mirabegron is a selective beta-3 adrenergic agonist, making it a relatively novel and well-tolerated option.

Get a Free Sample Report with Table of Contents@

https://www.expertmarketresearch.com/prefeasibility-reports/mirabegron-myrbetriq-manufacturing-plant-project-report/requestsample

Raw Materials for Mirabegron Production

The production of Mirabegron requires various raw materials and reagents, with the active pharmaceutical ingredient (API) being the most crucial. These materials include:

Active Pharmaceutical Ingredient (API) – Mirabegron:
Mirabegron is synthesized through a multi-step chemical process involving organic compounds. It requires high-purity chemicals and reagents for its synthesis.
Solvents:
Solvents like methanol, ethanol, and acetonitrile are used in various steps of the synthesis process. These solvents help dissolve starting materials and facilitate chemical reactions.
Reagents and Catalysts:
Specific chemical reagents and catalysts, such as acids, bases, and metal salts, are required in the chemical synthesis of Mirabegron to drive the reactions towards the formation of the desired product.
Excipients:
Excipients are inactive substances used to help deliver the active ingredient in the final dosage form. In the case of Mirabegron, excipients such as starch, lactose, magnesium stearate, and microcrystalline cellulose may be used in tablet formulations.
Packaging Materials:
Packaging materials include high-quality blister packs, bottles, and containers for the final product, ensuring it remains sterile and intact during storage and transport.

Mirabegron Manufacturing Process

The manufacturing process of Mirabegron can be broken down into several stages, including the synthesis of the active pharmaceutical ingredient (API), formulation of the drug, and packaging. Below is a step-by-step guide to the process:

1. API Synthesis (Mirabegron)

The first step in the manufacturing process is the synthesis of Mirabegron, which involves complex organic chemistry and multiple synthetic steps. The synthesis of Mirabegron typically involves the following:

Step 1: Preparation of Intermediates
The synthesis starts with the preparation of intermediate compounds. These intermediates are then modified in subsequent reactions to form the Mirabegron molecule.
Step 2: Chemical Reactions
Specific chemical reactions (such as amination, cyclization, or esterification) are used to modify the intermediates and generate the final Mirabegron compound. Reagents like acids, bases, and catalysts are added at various stages to drive the chemical reactions.
Step 3: Purification
After the reaction, the crude Mirabegron is purified to remove impurities. Common purification techniques used include recrystallization, chromatography, or filtration.
Step 4: Final Product Recovery
The purified Mirabegron is recovered and dried to obtain a powder or crystalline form. This is the active pharmaceutical ingredient (API) that will be used in the final drug formulation.

2. Formulation

Once the Mirabegron API has been synthesized and purified, it is combined with excipients to form the final dosage form (usually tablets or extended-release tablets). The formulation process includes:

Blending: The Mirabegron API is blended with excipients such as starch, lactose, and microcrystalline cellulose to form a homogeneous mixture.
Compression: The blended mixture is then compressed into tablet form using a tablet press.
Coating (if necessary): Some formulations may require coating, especially if the drug is to be extended-release. The coating helps control the release rate of Mirabegron into the bloodstream.

3. Packaging

After the tablets or capsules are manufactured, they undergo a final packaging process, which includes:

Blister Packaging: Individual tablets are placed into blister packs to protect them from moisture and contamination. Blister packaging also provides ease of dosage and tamper-evidence.
Bottle Packaging: For bulk packaging, the tablets may be bottled and labeled according to regulatory requirements.

The packaging must comply with regulatory guidelines and must ensure that the product remains stable during storage and transportation.

Plant Design and Infrastructure

Setting up a Mirabegron manufacturing plant requires the establishment of infrastructure and facilities that meet stringent pharmaceutical manufacturing standards. The design of the plant includes several key elements:

Raw Material Storage
A well-ventilated, temperature-controlled storage facility is necessary to store raw materials such as solvents, reagents, excipients, and the active pharmaceutical ingredient (API). Proper inventory management systems should be in place to track material usage and shelf life.
Production Area (Synthesis and Formulation)
The production area needs to be equipped with advanced machinery for chemical synthesis, blending, tablet compression, and coating. This area must comply with Good Manufacturing Practices (GMP) to ensure product quality and prevent contamination.
Quality Control Laboratory
A well-equipped quality control (QC) lab is essential for testing the purity, potency, and quality of the Mirabegron API, as well as the final formulation. The QC lab should have equipment for HPLC (High-Performance Liquid Chromatography), spectroscopy, and other analytical techniques.
Packaging Area
A clean, organized packaging area is crucial to ensure the integrity and safety of the product. Automated packing machines will speed up the process and minimize human errors. The packaging area must also ensure proper labeling, including dosage instructions and expiry dates.
Waste Management and Environmental Control
The plant must comply with environmental regulations related to waste disposal, air quality, and water management. Waste products such as solvents, by-products, and packaging materials must be handled according to local regulations.
Storage for Finished Products
The finished Mirabegron products must be stored in a controlled environment to maintain their stability. The storage area should be temperature and humidity-controlled to preserve the efficacy of the product until it is shipped to distribution channels.

Market Demand and Applications

The demand for Mirabegron has risen significantly due to the growing prevalence of overactive bladder (OAB) worldwide, particularly in aging populations. Key factors driving the market include:

Aging Population
With a rapidly aging global population, the demand for medications like Mirabegron for managing urinary disorders has increased.
Increasing Awareness of OAB
As awareness of overactive bladder grows, more patients are seeking treatment options, driving demand for Myrbetriq and similar drugs.
Global Market Expansion
While Myrbetriq has been established in developed markets such as North America and Europe, emerging markets in Asia and Latin America represent significant growth opportunities due to improved healthcare access and rising awareness of urinary disorders.
Pharmaceutical Market Trends
The trend toward safer, more targeted treatments with fewer side effects also benefits Mirabegron, as it is generally better tolerated than traditional antimuscarinic medications.

FAQs

1. What is Mirabegron used for?

Mirabegron (Myrbetriq) is used to treat overactive bladder (OAB) symptoms, including frequent urination, urgency, and incontinence.

2. How is Mirabegron manufactured?

Mirabegron is synthesized through chemical processes involving organic compounds, followed by formulation into tablets or extended-release tablets.

3. What raw materials are needed for Mirabegron production?

The key raw materials include chemical reagents for synthesis, excipients for tablet formulation, and solvents for purification.

4. What are the regulatory requirements for manufacturing Mirabegron?

Manufacturing Mirabegron requires compliance with regulatory bodies such as the FDA, EMA, and local health authorities, adhering to Good Manufacturing Practices (GMP).

5. What is the global market demand for Mirabegron?

The demand for Mirabegron is increasing due to the rising prevalence of overactive bladder (OAB), particularly among aging populations and in emerging markets.

https://www.expertmarketresearch.com.au/reports/australia-logistics-market

https://www.expertmarketresearch.com.au/reports/australia-lubricants-market

Media Contact:

Company Name: Claight Corporation

Contact Person: Lewis Fernandas, Corporate Sales Specialist — U.S.A.

Email: [email protected]

Toll Free Number: +1–415–325–5166 | +44–702–402–5790

Address: 30 North Gould Street, Sheridan, WY 82801, USA

Website: www.expertmarketresearch.com

Aus Site: https://www.expertmarketresearch.com.au